Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2023.07.31.551282v1?rss=1

Authors: Llambrich, S., Tielemans, B., Saliën, E., Atzori, M., Wouters, K., Van Bulck, V., Platt, M., Vanherp, L., Gallego Fernandez, N., Grau de la Fuente, L., Poptani, H., Verlinden, L., Himmelreich, U., Croitor, A., Attanasio, C., Callaerts-Vegh, Z., Gsell, W., Martinez-Abadias, N., Vande Velde, G.

Abstract:
Down syndrome (DS) is characterized by skeletal and brain structural malformations, cognitive impairment, altered hippocampal metabolite concentration and gene expression imbalance. These alterations were usually investigated separately, and the potential rescuing effects of green tea extracts enriched in epigallocatechin-3-gallate (GTE-EGCG) provided disparate results due to different experimental conditions. We overcame these limitations by conducting the first longitudinal controlled experiment evaluating genotype and GTE-EGCG prenatal chronic treatment effects before and after treatment discontinuation. Our findings revealed that the Ts65Dn mouse model reflected the pleiotropic nature of DS, exhibiting brachycephalic skull, ventriculomegaly, reduced bone mineral density, neurodevelopmental delay, hyperactivity, and impaired long-term memory with altered hippocampal metabolite concentration and gene expression. However, Ts65Dn mice showed milder phenotypes than previously described, suggesting a drift of the mouse model. GTE-EGCG treatment modulated most systems simultaneously but did not rescue DS phenotypes. On the contrary, the treatment exacerbated trisomic phenotypes including body weight, tibia microarchitecture, neurodevelopment, adult cognition, and metabolite concentration, not supporting the therapeutic use of a prenatal chronic treatment. Our results highlight the importance of longitudinal experiments assessing the co-modulation of multiple systems throughout development when characterizing preclinical models in complex disorders and evaluating the pleiotropic effects and general safety of pharmacological treatments.

Copy rights belong to original authors. Visit the link for more info

Podcast created by Paper Player, LLC